Unfortunately, we don‘t know explicitly. Only common sense...

Unfortunately, we don‘t know explicitly. Only common sense regarding market size, market participants, patent expirations and the lack of alternative pipeline products aiming at better vision outcomes make it very likely that such talks are ongoing, I‘d say.

A very small hint into such negotiations going on behind the scenes could be the following remark OPT added just very recently to their presentations saying:
“Concentrated prescriptions in U.S. enables potential self-commercialization opportunity with lean and targeted organization“

Conversely saying „We will partner ex-US“? „And are in discussions in doing so“?

Admittedly, a small hint only, but still...